Efficacy and Safety of an Adjustable Glaucoma Drainage Device (eyewatch System) for Refractory Glaucoma: A 2-Year Prospective Study.

In this study, we report a two-year follow-up after implantation of an adjustable glaucoma drainage device combined to a novel orbital filtering plate. The IOP was efficiently controlled post-operatively with limited complications and an excellent safety profile. To report the clinical results at two years after implantation of an eyeWatch system, which comprises of an adjustable glaucoma drainage device (eyeWatch implant) combined with a novel orbital filtering plate (eyePlate), in refractory glaucoma. Monocentric, prospective, non-comparative clinical trial. Patients suffering from refractory glaucoma after several failed surgeries were operated using the eyeWatch system. The primary outcome was the success rate, defined as an IOP ≤18 mmHg and reduction of more than 20% from baseline, IOP ≥6 mmHg. Secondary outcomes were mean IOP, visual acuity, number of anti-glaucoma medications, number and type of complications. Forty-two eyes from 42 patients were included. The mean follow-up time was 22.0±4.0 months. The mean baseline IOP decreased from 23.2±7.2 mmHg before surgery to 11.9±4.4 mmHg at 12 months (P<0.001) and to 11.5±3.0 at 24 months. The mean number of glaucoma medications decreased from 2.9±0.9 before surgery to 0.7±0.9 at 12 months (P<0.001) and to 1.0±0.9 at 24 months. The qualified success rate was 93% at 12 months and 90% at 24 months whereas the complete success rate was 46% and 40% at 12 and 24 months, respectively. Complications occurred in on 7 patients. Implantation of the eyeWatch system effectively lowered IOP and reduced glaucoma medications for a 2-year period in patients who had previous failed glaucoma surgery. Persistent hypotony was not observed and the number of complications was low.

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.